Instil Bio, Inc. (TIL)

Instil Bio's stock price decreased by 29.5% from January 1st, 2026, to February 6, 2026. Key events include the discontinuation of AXN-2510 development, which led to a 15% stock drop and analyst downgrades. The company reported Q3 2025 earnings miss. Analysts have significantly decreased price targets for TIL. The stock holds a buy signal from the short-term Moving Average, but a general sell signal from the long-term average.

Instil Bio's products are in development, so there is no demand seasonality. The company is focused on advancing its therapies through clinical trials and regulatory pathways.

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer, utilizing its TaaS platform to manufacture and deliver T-cell therapies. Its pipeline includes ITIL-168 for melanoma and solid tumors, ITIL-306 targeting solid tumors like ovarian and lung cancer, AXN-2510/IMM2510 (discontinued in January 2026), INB-101 for refractory solid tumors, and the INB-200 series to improve tumor antigen recognition. The company is also exploring applications beyond oncology.

Instil Bio is headquartered in Dallas, Texas, and was founded in 2018 in both the United Kingdom and the United States. While its primary operations are in the US, it has conducted clinical trials in other regions, including China.

Instil Bio's brand reputation has been impacted by clinical setbacks and market performance. The company has a consensus analyst rating of "Reduce" or "Hold". The discontinuation of AXN-2510 development negatively impacted its reputation. Instil Bio underperformed the US Biotechs industry and the broader US Market over the past year. The significant decline in stock price has negatively affected investor confidence.

Instil Bio has 67 institutional owners and shareholders holding 4,687,392 shares. Major institutional owners include Curative Ventures V LLC, BML Capital Management, LLC, CPMG Inc, Vivo Capital, LLC, Siren, L.L.C., Millennium Management Llc, Vanguard Group Inc, Sectoral Asset Management Inc, Morgan Stanley, and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. CEO Bronson Crouch directly owns 1.72% of the company's shares.